BIRD Newsletter I
BIRD has been supporting US-Israeli partnerships for almost 29 years in diverse areas: Telecommunications, Electronics and Semiconductors, Software and Medical Devices. In the 90s, BIRD started supporting Biotechnology projects and after 9/11, BIRD entered the area of Homeland Security.
Recently, we have been looking at two emerging areas: Alternative Energy and Water.
Over the last two decades there has been a 40% increase in the worldwide water use. There is an increasing awareness that without action, this steady increase may lead to water scarcity for a large percentage of humanity. One of the aspects in dealing with this possible emerging crisis is advanced Water Technology, which is being developed to deal with water recycling, water security, water-efficient systems for industrial applications and others.
Companies interested in pursuing a US-Israeli partnership in one of the aforementioned areas, may approach BIRD to discuss the opportunity. Our contact information and the proposal deadlines can be accessed through this newsletter.
This section features highlights of BIRD funded projects and success stories emanating from our activities. The Stories here appear in modified, simplified form; for full details and quotations, please use the links to the official BIRD press releases.
ARRIS (www.arrisi.com), a leading American provider of broadband access and cable telephony solutions, and Israeli Resolute Networks Ltd. (www.resolutenetworks.com), teamed together for an 18 months project, supported by a BIRD grant of $1.1 Million, in which the companies succeeded in developing the industry’s first end-to-end solution for cable/multi-service operators which enables provisioning of T1/E1 voice, frame relay, and leased line services over the existing cable (DOCSIS) infrastructure, potentially serving hundreds of thousands of businesses.
The joint ARRIS-Resolute solution, the “ARRIS Touchstone® Commercial Services Modem”, will be marketed by ARRIS to key multi service operators. We at BIRD look forward to the rapid adoption of this solution and expect full repayment of the grant in a relatively short period of time.
Read the official, detailed press release HERE
American Telcordia Technologies (www.telcordia.com) and Israeli Unipier (www.unipier.com) have recently received a grant from the BIRD Foundation to develop a solution for intelligent, policy-based hand-off (switching) between communications networks based on different technologies
Dr. Shoshana Loeb, Executive Director of Network Systems Research at Telcordia
Read the official, detailed press release HERE
(BACK TO TOP)
On April 25th, 2006, BIRD Foundation invited Israeli Executives to take part in a breakfast event hosted by Google's product management leadership. Google’s Jonathan Rosenberg, SVP Product Management and Marketing and Susan Wojcicki, VP Product Management gave a fascinating presentation about the company’s strategy.
The presentation revealed, among other things, Google's approach to advancing creativity and self-initiatives by product engineers, which includes providing all engineers what Google calls "20% time" - a day a week to work on personal "pet projects” which they believe would best advance the company
as well as providing engineers the flexibility to chose the projects they work on - effectively "voting" on what would be the most successful and interesting projects. Also discussed, was Google's "barrier bashing" approach to product management - thinking out-of-the-box and taking constant advantage of technology trends (increase in computing power, bandwidth, etc).
as well as providing engineers the flexibility to chose the projects they work on - effectively "voting" on what would be the most successful and interesting projects.
Also discussed, was Google's "barrier bashing" approach to product management - thinking out-of-the-box and taking constant advantage of technology trends (increase in computing power, bandwidth, etc).
A TRIDE* delegation from Israel, lead by its new Executive Director, Dr.
Since its inception in 1996, TRIDE has invested $1M in three projects; In December 2005, an additional $1M of funding was provided by the three countries. The meeting in
The next round of projects seeking funding will be presented at the upcoming meeting of the TRIDE Executive Committee. Companies interested in submitting projects as candidates for TRIDE funding should contact the TRIDE / BIRD office in Tel-Aviv.
The Executive Committee members are: Dr.
The TRIDE model consists of a partnership between three companies, one from each country, cooperating in an R&D project to develop a commercial product for the global market. TRIDE co-shares the cost with the three companies on an approximately equal basis. READ MORE…
* TRIDE is the Israel-Jordan-US (Trilateral) Industrial Development Fund, established in 1996.
During their stay, Pfizer representatives Dr. David Rosen, Head of Development and Commercial Strategic Alliances and Mr. Ilya Oshman, Vice President of Pfizer Strategic Investments Group visited venture capital groups, incubators, university technology transfer groups and individual company representatives. An entire morning was spent with BIRD Foundation representatives, reviewing BIRD’s portfolio of new companies and new technologies. During the visit, Mr. Oshman and Dr. Rosen also met with the Ministry of Industry and Trade and the Office of the Chief Scientist to discuss future opportunities for research and for investment in Pfizer’s Dr. Rosen noted that “The meetings began early each morning and continued hourly until into the late evening each day. Despite an intensive schedule, we were only able to visit with about half of the companies that were of interest to us during our first visit to
Pfizer’s Dr. Rosen noted that “The meetings began early each morning and continued hourly until into the late evening each day. Despite an intensive schedule, we were only able to visit with about half of the companies that were of interest to us during our first visit to
Three top executives from
The Israeli companies included were Disc-O-Tech Medical Technologies, Kineticure, Orthomeditec, SunLight Medical, OrthoMechanics and DMMT. These companies were pre-selected by BSN Medical prior to the mission from a group of over fifteen relevant Israeli orthopedic companies introduced to BSN Medical by BIRD.
Representing BSN Medical were the President and the VP of Marketing of the Orthopedics Global Business Unit and the VP of Operations of the The mission was initiated and organized by BIRD’s staff, including Limor Nakar-Vincent - East Coast Representative, BSN medical is a manufacturer that specializes in orthopedic medical devices for wound care, casting, bandaging, and phlebotomy. The company has a workforce of over 3,000 employees worldwide and offices in over 33 countries, including manufacturing facilities in France, Germany, Ireland, Mexico, Pakistan, South Africa, the UK and the U.S. BSN medical owns and operates some of the largest brands of casting, splinting and bandaging market, and is one of the most focused non-invasive musculoskeletal repair company, globally.
The mission was initiated and organized by BIRD’s staff, including Limor Nakar-Vincent - East Coast Representative,
BSN medical is a manufacturer that specializes in orthopedic medical devices for wound care, casting, bandaging, and phlebotomy. The company has a workforce of over 3,000 employees worldwide and offices in over 33 countries, including manufacturing facilities in France, Germany, Ireland, Mexico, Pakistan, South Africa, the UK and the U.S. BSN medical owns and operates some of the largest brands of casting, splinting and bandaging market, and is one of the most focused non-invasive musculoskeletal repair company, globally.
A delegation of 3 senior executives from Lilly Ventures, the venture capital arm of Eli Lilly and Company (currently manages $175M), visited Israel in late April 2006 in order to locate and identify new ideas and early stage companies in its areas of interest.
The visit was coordinated with BIRD; The BIRD Foundation presented about fifty companies and technology transfer offices to Lilly Ventures, of which ten were identified as relevant. Meetings with these companies’ representatives took place at Lilly’s offices in
Lilly Ventures is the venture capital arm of Eli Lilly and Company, a leading innovation-driven pharmaceutical company ($15 B annually). Its primary goal is to facilitate the success of companies in Lilly’s areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $175M under management and focuses on three major areas of interest: Biotechnology, Healthcare IT and Medical Technology.
BIRD’s West Coast representative, Michal Miasnik, took the lead in organizing this visit, also assisted by Yuval Weiss.
This section features highlights of changes and developments regarding BIRD’s representatives and personnel.
At the conclusion of over eight years at BIRD as its Programs Director, just before I head on to meet new challenges as the CEO of an emerging medical devices company, I look back on those exceptionally interesting and rewarding years at BIRD, feeling that I have been very fortunate. The Israeli and American entrepreneurs and technologists, considered as "the cream of the crop" of society, with whom I've been privileged to work, the wide range of exciting, state-of-the-art technologies which I've been exposed to, and the challenging objective to promote cooperation between relatively dissimilar business entities through a "match-making" process, all justify my feeling of satisfaction as I reflect back on my tenure at BIRD. Yet, most of all, I owe my achievements to my colleagues and others in BIRD's network, who have been dedicated partners and superb teammates throughout, and to whom I'm very grateful.
BIRD has selected the American-Israel Chamber of Commerce, Southeast Region (www.aiccse.org) to represent it in
“Through our new relationship with AICC, we expect to significantly expand our reach in the Southeast, an area of the
BIRD has been active in the Southeast especially in
Dr. Maron served until recently as the Managing Director of the Research Institute for Nanoscience and Nanotechnology at the
Previously, Dr. Maron was deputy R&D director at TARO Pharmaceuticals where he focused his efforts in R&D renewal, leading to an outstanding pipeline. Dr. Maron also spent three years as Senior Researcher at Merck Sharp and Dohme, working in physiological NMR and analytical methods. After his return to
Dr. Maron graduated from the Hebrew University of Jerusalem and was a postdoctoral fellow at
IN ORDER FOR YOUR PROPOSAL TO BE ELIGIBLE FOR THE BOARD'S REVIEW, THE FOLLOWING ARE THE FINAL DATES FOR SUBMISSION:
Thursday, September 14th, 2006 – Executive Summary of the Proposal
Thursday, October 26th, 2006 – Final Proposal